EVT 302 + Placebo + EVT 302 plus open label Nicotine replacement + Placebo plus open label Nicotine Replacement

Phase 2Completed
0 watching 0 views this week Active
47
Hype Score

Development Stage

Pre-clinical
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Smoking Cessation

Conditions

Smoking Cessation

Trial Timeline

Aug 1, 2008 → May 1, 2009

About EVT 302 + Placebo + EVT 302 plus open label Nicotine replacement + Placebo plus open label Nicotine Replacement

EVT 302 + Placebo + EVT 302 plus open label Nicotine replacement + Placebo plus open label Nicotine Replacement is a phase 2 stage product being developed by Evotec for Smoking Cessation. The current trial status is completed. This product is registered under clinical trial identifier NCT00738595. Target conditions include Smoking Cessation.

Hype Score Breakdown

Clinical
17
Activity
12
Company
5
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT00738595Phase 2Completed

Competing Products

20 competing products in Smoking Cessation

See all competitors
ProductCompanyStageHype Score
Brenipatide + PlaceboEli LillyPhase 2
52
Nicotine + Nicotine + NicotineJohnson & JohnsonPhase 2
52
Nicotine replacement therapy + Nicotine replacement therapyJohnson & JohnsonPhase 2
52
Nicotine Patch + Placebo PatchJohnson & JohnsonPhase 1
33
Nicotine Patch + Placebo Patch + SLS Comparator PatchJohnson & JohnsonPhase 1
33
Nicotine + PlaceboJohnson & JohnsonPre-clinical
23
Nicotine Patch + Nicotine Patch Comparator + Placebo PatchJohnson & JohnsonPhase 1
33
Nicotine Patch + Placebo Patch + No Patch ControlJohnson & JohnsonPhase 1
33
Nicotine gum + Placebo gum + Nicotine inhaler + Placebo inhalerJohnson & JohnsonPhase 3
77
Nicotine patch, nicotine inhaler, bupropion + Nicotine patchJohnson & JohnsonApproved
85
AZD4041 + PlaceboAstraZenecaPhase 1
33
taranabantMerckPhase 2
52
Nicotine replacement therapyNovartisPre-clinical
23
AFQ065NovartisPhase 1
33
Liraglutide + PlaceboNovo NordiskPhase 2
51
VareniclinePfizerPhase 2
51
placebo + Varenicline TartaratePfizerPhase 3
76
varenicline + placeboPfizerApproved
84
varenicline (CP-526,555)PfizerPhase 3
76
placebo + vareniclinePfizerApproved
84